Article Details

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with ... - PR Newswire

Retrieved on: 2024-11-20 14:34:06

Tags for this article:

Click the tags to see associated articles and topics

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with ... - PR Newswire. View article details on hiswai:

Summary

The article discusses Genprex's gene therapy advancements for ALK-positive lung cancer treatment, specifically using REQORSA in combination with ALK inhibitors, highlighting capital markets' interest in innovative cancer treatments and gene therapy solutions. Tags like 'Non-small-cell lung cancer' and 'ALK inhibitor' relate to this context.

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo